Back

SLD5/GINS4 controls dynein-dependent centrosome maturation and exposes a candidate mitotic vulnerability in cancer.

Kumar, V.; Singh, V.; Singh, R.; Kumar, P.; Ghosh, T.

2026-05-11 cancer biology
10.64898/2026.05.07.723511 bioRxiv
Show abstract

Faithful proliferation requires coordinated DNA replication with centrosome maturation and spindle-pole integrity. SLD5, encoded by GINS4, is a core component of the GINS replication complex and is frequently elevated in tumors, but whether it links replication-associated cancer states to centrosome control has remained unclear. Here, we show that GINS4/SLD5 is recurrently upregulated across human cancers at transcript and protein levels and marks tumor programs enriched for DNA replication, chromosome segregation, and mitotic control. In cancer cells, Sld5 depletion dispersed PCM1, AZI1, and CEP290-positive centriolar satellites without eliminating these satellite proteins, reduced dynein heavy chain expression, and destabilized dynein-dynactin localization at spindle poles. Direct depletion of dynein heavy chain, co-depletion analyses, and pharmacological inhibition of dynein motor activity with ciliobrevin D phenocopied Sld5 loss, causing satellite dispersion, defective recruitment of PLK1, Aurora A, CEP192, and CEP215 to centrosomes, and multipolar spindle formation. These defects occurred without detectable DNA damage or checkpoint activation, indicating a non-canonical Sld5 function beyond its role in the replisome. Cancer dependency and kinase network analyses further nominate SLD5-associated mitotic and checkpoint pathways as therapeutic targets. Our findings identify SLD5/GINS4 as a regulator of dynein-dependent centrosome maturation and a candidate vulnerability in replication-driven cancers, with potential value for biomarker-guided therapeutic stratification. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=136 SRC="FIGDIR/small/723511v1_ufig1.gif" ALT="Figure 1"> View larger version (53K): org.highwire.dtl.DTLVardef@e845d8org.highwire.dtl.DTLVardef@141719aorg.highwire.dtl.DTLVardef@1895e1corg.highwire.dtl.DTLVardef@181aa16_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Cell Reports
1338 papers in training set
Top 2%
12.1%
2
Nature Communications
4913 papers in training set
Top 17%
10.3%
3
Cancer Cell
38 papers in training set
Top 0.2%
6.3%
4
Molecular Cell
308 papers in training set
Top 3%
6.2%
5
Cancer Research
116 papers in training set
Top 0.6%
4.2%
6
Cell Genomics
162 papers in training set
Top 1%
3.6%
7
Cancer Discovery
61 papers in training set
Top 0.6%
3.5%
8
Advanced Science
249 papers in training set
Top 6%
3.2%
9
The EMBO Journal
267 papers in training set
Top 0.5%
3.0%
50% of probability mass above
10
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 25%
2.7%
11
Oncogene
76 papers in training set
Top 0.7%
2.3%
12
Nature
575 papers in training set
Top 10%
2.0%
13
iScience
1063 papers in training set
Top 16%
1.7%
14
Cell Reports Medicine
140 papers in training set
Top 4%
1.7%
15
eLife
5422 papers in training set
Top 43%
1.7%
16
Developmental Cell
168 papers in training set
Top 8%
1.7%
17
Science Advances
1098 papers in training set
Top 18%
1.7%
18
Clinical Cancer Research
58 papers in training set
Top 1%
1.7%
19
Cell
370 papers in training set
Top 13%
1.5%
20
Communications Biology
886 papers in training set
Top 13%
1.3%
21
Nature Cell Biology
99 papers in training set
Top 4%
1.2%
22
Science Signaling
55 papers in training set
Top 0.2%
1.2%
23
Genome Medicine
154 papers in training set
Top 7%
0.9%
24
Cell Chemical Biology
81 papers in training set
Top 3%
0.9%
25
Journal of Clinical Investigation
164 papers in training set
Top 5%
0.9%
26
Cell Death & Disease
126 papers in training set
Top 3%
0.7%
27
EMBO Molecular Medicine
85 papers in training set
Top 5%
0.7%
28
EMBO reports
136 papers in training set
Top 6%
0.7%
29
PLOS Biology
408 papers in training set
Top 20%
0.7%
30
Cell Death & Differentiation
48 papers in training set
Top 0.8%
0.7%